NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
KAPVAY (clonidine hydrochloride) by Teva is clinical pharmacology clonidine stimulates alpha-adrenoreceptors in the brain stem. First approved in 2009.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAPVAY is an extended-release oral tablet formulation of clonidine hydrochloride, an alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system. It is indicated for attention-deficit/hyperactivity disorder (ADHD) and works by decreasing peripheral resistance, heart rate, and blood pressure through brainstem alpha-adrenoreceptor stimulation. The drug achieves antihypertensive effect within 30-60 minutes of oral administration with maximum effect in 2-4 hours.
$0.008BPart D
LOE ApproachingApproaching loss of exclusivity with minimal Part D spending suggests a niche market position; limited team expansion likely as product enters generic competition phase.
Mechanism of Action
CLINICAL PHARMACOLOGY Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride…
Worked on KAPVAY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.